Study of Descartes-30 in Acute Respiratory Distress Syndrome

Purpose

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Conditions

  • Acute Respiratory Distress Syndrome
  • Covid19

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients must be 18 years of age or older at the time of enrollment - Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS

Exclusion Criteria

  • Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA. - Patient is in moribund state with expected survival <24 hours.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Descartes 30
  • Biological: Descartes 30
    Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Recruiting Locations

More Details

NCT ID
NCT04524962
Status
Terminated
Sponsor
Cartesian Therapeutics